The global athlete’s foot therapeutics market reach a value of US$735.4 million by 2019.

Monday 12 March 2012, Amsterdam

Pharmaceuticals companies that have previously shied away from developing treatments for athlete’s foot due to market competitiveness should instead look to niche areas of the disease for commercial opportunity, a new study by business intelligence provider.

The new report indicates that, although drug developers may have refrained from entering the competitive athlete’s foot therapeutics market due to the number of treatments already available, an unmet need still exists for cases of resistant athlete’s foot infections. These cases require first-in-class (FIC) anti-fungal drugs and cannot be treated with the available therapies.

The current athlete’s foot therapeutics market is highly competitive, with more than 10 marketed products. The market is dominated by generics classes such as azoles, allylamines and benzylamines, which offer good safety and tolerability profiles, thereby creating strong competition among these products. This increases the difficulty for new entrants by offering only a small window of opportunity to capture market share.

Adding to this difficulty is slow market growth, which could be attributed to the reluctance of athlete’s foot patients to visit doctors for treatment due to the perception that the disease is not a serious infection and the ability to treat the disease with over-the-counter (OTC) drugs in the initial stages.

However, they found that the product pipeline for athlete’s foot is weak and, as there are no FIC molecules in the late stage of development, companies have an opportunity to capitalize on this gap in the market. In Phase III, there are three product extensions, which, upon their launch, are not expected to have an impact on the market. There are also FIC molecules in Phase II with novel mechanisms of action, but they will not enter the market until the next decade.

An analysis shows that the global athlete’s foot therapeutics market stood at a value of US $490.0 million in 2006 and grew at a compound annual growth rate (CAGR) of 3.4% to reach US$580.5 million in 2011. Despite factors that may contribute to slow market growth over the next eight years, they forecasts that the global athlete’s foot therapeutics market will continue to demonstrate a similar CAGR of 3.0% to reach a value of US$735.4 million by 2019.

Athlete’s Foot Therapeutics - Pipeline Assessment and Market Forecasts to 2019

The report is an essential source of information and analysis on the global athlete's foot therapeutics market. The report identifies the key trends shaping and driving the market, while analysis into the prevalent competitive landscape distinguishes the emerging players expected to significantly alter the market positioning of the current leaders. Most importantly, the report provides valuable insights into the pipeline products expected to appear within the global athlete's foot therapeutics sector within the next eight years.